Endoscopic Resection for Small Rectal Neuroendocrine Tumors
Launched by GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL · Mar 24, 2025
Trial Information
Current as of April 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
We aimed to conduct a muticenter randomized controlled trial to compare mEMR-C with mEMR-L for the treatment of small rectal neuroendocrine tumors (NETs) in ten tertiary hospitals in China.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age from 18 to 80 years;
- • 2. With a high suspicion or evidence of rectal NET assessed using EUS or colonoscopy;
- • 3. With tumor size ≤10 mm assessed by colonoscopy;
- • 4. Plan to receive mEMR-C or mEMR-L treatment and provide written informed consent;
- Exclusion Criteria:
- • 1. Unable to tolerate mEMR-L or mEMR-C as assessed by the research team of each center;
- • 2. Complicated with serious diseases such as malignant tumor, which may lead to shorter life expectancy, the research team considers that it is not suitable for inclusion in the study after comprehensive evaluation;
- • 3. Rectal NET with lymph node metastasis or distant metastasis;
- • 4. Received resection of rectal neuroendocrine tumor by other surgical procedures;
- • 5. Multiple rectal neuroendocrine tumors;
- • 6. Vulnerable groups such as pregnant women or patients with mental disorders;
- • 7. Poor compliance, unable to cooperate with treatment.
About Guangdong Provincial People's Hospital
Guangdong Provincial People's Hospital is a leading tertiary healthcare institution located in Guangdong Province, China, renowned for its comprehensive medical services and advanced research capabilities. As a prominent clinical trial sponsor, the hospital is dedicated to advancing medical science through innovative research and the rigorous evaluation of new therapies and interventions. With a multidisciplinary team of experienced clinicians and researchers, the institution prioritizes patient safety and ethical standards while fostering collaborations with academic and industry partners to enhance healthcare outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported